Prescient Therapeutics

Prescient Therapeutics FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of Prescient Therapeutics (PTX.AX) as of Nov 22, 2026 is 103.16 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 98.92 % — a change of 4.29% (higher).

FCF Conversion

103.16 %

YoY

4.29%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of Prescient Therapeutics is 2026 103.16 % . FCF Conversion Rate (FCF/EBITDA) of Prescient Therapeutics was 2025 98.92 % . It decreases by 4.29% higher compared to the previous year.

The Prescient Therapeutics FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2019
110.55 AUD
Jan 1, 2020
69.84 AUD
Jan 1, 2021
95.74 AUD
Jan 1, 2022
84.37 AUD
Jan 1, 2023
88.38 AUD
Jan 1, 2024
89.80 AUD
Jan 1, 2025
98.92 AUD
Jan 1, 2026
103.16 AUD
The Prescient Therapeutics FCF Conversion history
YEARFCF ConversionYoY
103.16 %+4.29%
98.92 %+10.15%
89.80 %+1.61%
88.38 %+4.76%
84.37 %-11.88%
95.74 %+37.08%
69.84 %-36.82%
110.55 %+32.31%
83.55 %-34.59%
127.74 %+43.62%
88.95 %-31.39%
129.64 %+32.21%
98.06 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Prescient Therapeutics Stock analysis

What does Prescient Therapeutics do? Prescient Therapeutics Ltd is an Australian biotechnology company focused on developing novel cancer therapies. The company was founded in 2006. Its business model is based on leveraging modern technologies and research findings to develop innovative solutions for cancer treatment. Prescient Therapeutics operates in two segments: drug development and research services. The company collaborates closely with leading scientists and medical institutions to utilize the latest advancements in cancer research and bring new drugs to the market. One of its products, PTX-200, is a novel inhibitor of protein kinase CK2 that has shown efficacy in clinical studies against various types of cancer. Another important product is OmniCAR, a next-generation CAR-T cell therapy that allows for selective recognition and destruction of cancer cells. Prescient Therapeutics aims to solidify its position as a leading provider of innovative cancer treatments through a rigorous validation strategy and collaboration with doctors and patients. The company has made significant progress in the development of new cancer therapies, holding numerous patents and establishing partnerships with leading medical institutions. Its goal is to meet the unmet needs of cancer patients and create a better future for cancer therapy. Prescient Therapeutics is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Prescient Therapeutics stock

FCF Conversion Rate (FCF/EBITDA) of Prescient Therapeutics is 103.16 % in 2026.

FCF Conversion Rate (FCF/EBITDA) of Prescient Therapeutics changed from 98.92 % to 103.16 %, representing a 4.29% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) Prescient Therapeutics since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s Prescient Therapeutics with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Prescient Therapeutics

All Key Metrics — Prescient Therapeutics